The Effect of Antidepressants on the Course of Inflammatory Bowel Disease

Abstract EN

Background and Aims.

Mood may have an important role in the natural history of inflammatory bowel disease (IBD).

However, the impact of antidepressant use on prognosis is unknown.

We aimed to address this in a longitudinal study in a referral population.

Methods.

We collected demographic data, clinical disease activity and mood using validated questionnaires, and antidepressant use at baseline.

Longitudinal disease activity was defined by disease flare or need for glucocorticosteroids, escalation of medical therapy, hospitalisation, or intestinal resection.

We compared rates of these over a minimum period of 2 years according to antidepressant use at baseline.

Results.

In total, 331 patients provided complete data, of whom 54 (15.8%) were taking an antidepressant at study entry.

Older age, female gender, and abnormal mood scores were associated with antidepressant use.

During longitudinal follow-up, there was a trend towards lower rates of any of the four endpoints of IBD activity of interest in patients with abnormal anxiety scores at baseline and who were receiving an antidepressant (42.3% versus 64.6%, P = 0.05).

Based on univariate Cox regression analysis, there was a trend towards lower rates of escalation of medical therapy among patients receiving antidepressants at baseline (hazard ratio (HR) = 0.59; 95% confidence interval (CI) 0.35-1.00, P = 0.05).

None of the differences observed persisted after multivariate Cox regression.

Conclusions.

Antidepressants may have some beneficial effects on the natural history of IBD, but larger studies with longer follow-up are required.

Whether these effects are limited to patients with abnormal mood remains uncertain.